SQZ Biotechnologies Company (SQZB)
OTCMKTS · Delayed Price · Currency is USD
0.0280
0.00 (0.00%)
Aug 1, 2025, 2:58 PM EDT

SQZ Biotechnologies Company Company Description

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions.

Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.

The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.

Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers.

The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

SQZ Biotechnologies Company
CountryUnited States
Founded2013
IndustryBiotechnology
SectorHealthcare
Employees53
CEOHoward Bernstein

Contact Details

Address:
200 Arsenal Yards Boulevard
Watertown, Delaware 02472
United States
Phone617 758 8672
Websitesqzbiotech.com

Stock Details

Ticker SymbolSQZB
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS78472W1045
SIC Code2836

Key Executives

NamePosition
Lawrence J. Knopf Esq.General Counsel and Secretary
Dr. Marshelle Smith Warren M.D.Chief Medical Officer
Dr. Robert S. Langer Jr., Ph.D., ScDCo-Founder and Member of Scientific Advisory Board
Ipsita Roymoulik Ph.D.Senior Vice President of CMC and QUALITY